Coherus BioSciences to Present at Bloomberg Intelligence Healthcare Event on February 12th
February 05 2016 - 9:30AM
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play,
global biosimilars company with late-stage clinical products, today
announced that Denny Lanfear, President and Chief Executive
Officer, will be a featured speaker at the 4th Annual Bloomberg
Intelligence Healthcare Event.
The discussion will be held on Friday, February 12 starting at
2:00 pm ET in New York City. Information regarding the event is
available at www.bloomberglp.com/healthcareevent2016.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play global biosimilar platform
company that develops and commercializes high-quality therapeutics
for major regulated markets. Biosimilars are intended for use in
place of existing, branded biologics to treat a range of chronic
and often life-threatening diseases, with the potential to reduce
costs and expand patient access. Composed of a team of proven
industry veterans with world-class expertise in process science,
analytical characterization, protein production and
clinical-regulatory development, Coherus is positioned as a leader
in the global biosimilar marketplace. Coherus is advancing three
late-stage clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and
CHS-1420 (adalimumab biosimilar), as well as developing a robust
pipeline of future products. For additional information, please
visit www.coherus.com.
INVESTOR AND MEDIA CONTACT:
Keith Vendola, M.D.
Investor Relations
Coherus BioSciences, Inc.
kvendola@coherus.com
+1 (650) 437-6239
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024